Prostate Cancer VTE in Sweden: Epidemiology and Anticoagulation Treatment of VTE
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 97,765
- 试验地点
- 1
- 主要终点
- Time between a first cancer-related and a recurrent VTE event
研究概览
简要总结
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary embolism) and is a leading cause of condition of being diseased and death among cancer patients. The goal of the study is to gather information how often venous thromboembolism (VTE) occurs in prostate cancer patients in Sweden and how this condition is treated with blood thinners.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Initially all patients newly diagnosed with PCa between 2007-2016 with at least one year before the end of follow up date (31 December 2017) will be included. From this population, a sub-population of PCa patients with a first cancer-related VTE event will be selected.
排除标准
- 未提供
研究组 & 干预措施
Men with Prostate Cancer (PCa)
干预措施: Rivaroxaban (Xarelto, BAY59-7939) (Drug)
Men with Prostate Cancer (PCa)
干预措施: Apixaban(Eliquis) (Drug)
Men with Prostate Cancer (PCa)
干预措施: Pradaxa (Dabigatran etexilate) (Drug)
结局指标
主要结局
Time between a first cancer-related and a recurrent VTE event
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa and a first cancer-related VTE event
Subject's socio-demographic at the date of an incident PCa diagnosis
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa
Incidence rate of cancer-related VTE
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa
Duration of treatment
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa and a first cancer-related VTE event； To characterize the long-term anticoagulation treatment
Subject's clinical characteristics at the date of an incident PCa diagnosis
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa
Cancer therapies in PCa at the initial time after diagnosis
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa
Choice of drug
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa and a first cancer-related VTE event； To characterize the long-term anticoagulation treatment
Occurrence of recurrent VTE events
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa and a first cancer-related VTE event； By long-term anticoagulation treatment (LMWH (Low molecular weight heparin), VKA (Vitamin K anticoagulants) or NOAC (Non-vitamin K oral anticoagulation)) and its estimated duration (up 3 months, 3-6 months, more than 6 months)
Incidence rates of post-VTE bleeding events leading to hospitalization, and mortality by anticoagulation treatment
时间窗: Retrospective analysis between 2007 and 2016
Among men with PCa and a first cancer-related VTE event
次要结局
- Subject's socio-demographic at the time of inclusion into the database(Retrospective analysis between 2007 and 2016)
- Subject's clinical characteristics at the time of inclusion into the database(Retrospective analysis between 2007 and 2016)
- Incidence rate of VTE events(Retrospective analysis between 2007 and 2016)